- Home
- CTOR vs BLUE Comparison
CTOR vs BLUE Comparison
Compare CTOR & BLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOR
- BLUE
- Stock Information
- Founded
- CTOR 2021
- BLUE 1992
- Country
- CTOR United States
- BLUE United States
- Employees
- CTOR N/A
- BLUE N/A
- Industry
- CTOR
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CTOR
- BLUE Health Care
- Exchange
- CTOR NYSE
- BLUE Nasdaq
- Market Cap
- CTOR 89.9M
- BLUE 85.4M
- IPO Year
- CTOR N/A
- BLUE 2013
- Fundamental
- Price
- CTOR $1.30
- BLUE $9.18
- Analyst Decision
- CTOR Strong Buy
- BLUE Hold
- Analyst Count
- CTOR 2
- BLUE 9
- Target Price
- CTOR $4.50
- BLUE $49.14
- AVG Volume (30 Days)
- CTOR 275.1K
- BLUE 537.5K
- Earning Date
- CTOR 12-27-2024
- BLUE 11-14-2024
- Dividend Yield
- CTOR N/A
- BLUE N/A
- EPS Growth
- CTOR N/A
- BLUE N/A
- EPS
- CTOR N/A
- BLUE N/A
- Revenue
- CTOR N/A
- BLUE $53,120,000.00
- Revenue This Year
- CTOR N/A
- BLUE $152.71
- Revenue Next Year
- CTOR N/A
- BLUE $233.91
- P/E Ratio
- CTOR N/A
- BLUE N/A
- Revenue Growth
- CTOR N/A
- BLUE 144.50
- 52 Week Low
- CTOR $0.85
- BLUE $5.80
- 52 Week High
- CTOR $49.00
- BLUE $38.40
- Technical
- Relative Strength Index (RSI)
- CTOR N/A
- BLUE 53.78
- Support Level
- CTOR N/A
- BLUE $7.75
- Resistance Level
- CTOR N/A
- BLUE $9.14
- Average True Range (ATR)
- CTOR 0.00
- BLUE 1.21
- MACD
- CTOR 0.00
- BLUE 0.08
- Stochastic Oscillator
- CTOR 0.00
- BLUE 83.81
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.